▸ 3 Nov 2026, 10:09 Marine Biomedical Achieves FDA Clearance Company Update
▸ 2 Nov 2026, 08:32 Strongest U.S. Remplir Sales Month Since Launch Company Update
▸ 22 Oct 2026, 09:00 Q1 FY27 OCC Investor Presentation Presentations
▸ 22 Oct 2026, 08:57 Quarterly Activity Report & Appendix 4C Quarterly Reports
▸ 20 Oct 2026, 08:57 Orthocell Investor Webinar Details Presentations
▸ 13 Oct 2026, 09:11 Remplir Shows Excellent Early Prostatectomy Results Company Update
▸ 2 Oct 2026, 16:16 Letter to Shareholders, Notice of AGM & Proxy Form Meetings & Governance
▸ 2 Oct 2026, 11:04 Change of Auditor Other
▸ 21 Sep 2026, 08:55 Orthocell Achieves First Remplir Sales in Thailand Company Update
▸ 11 Sep 2026, 15:14 Cleansing Notice Securities Administration
▸ 11 Sep 2026, 15:08 Application for quotation of securities - OCC Securities Administration
▸ 10 Sep 2026, 08:30 Date of AGM & Closing Date for Director Nominations Meetings & Governance
▸ 31 Aug 2026, 12:57 Appendix 4G Company Administration
▸ 31 Aug 2026, 12:57 Corporate Governance Statement Company Administration
▸ 31 Aug 2026, 12:56 Appendix 4E & Annual Report Financial Results
▸ 12 Aug 2026, 08:27 Orthocell Canaccord Genuity Conference Live Webcast Presentations
▸ 11 Aug 2026, 08:45 Orthocell to Present at Canaccord Growth Conference Presentations
▸ 3 Aug 2026, 08:38 Change of Registered Office & Principal Place of Business Securities Administration
▸ 20 Jul 2026, 18:10 Appendix 3Y - John Van Der Wielen Director Interests
▸ 20 Jul 2026, 18:06 Application for quotation of securities - OCC Securities Administration
▸ 17 Jul 2026, 16:42 Appendix 3Y x 4 Director Interests
▸ 17 Jul 2026, 16:36 Application for quotation of securities - OCC Securities Administration
▸ 17 Jul 2026, 13:31 Notification regarding unquoted securities - OCC Securities Administration
▸ 17 Jul 2026, 13:30 Notification regarding unquoted securities - OCC Securities Administration
▸ 17 Jul 2026, 10:07 Option Terms and Conditions Securities Administration
▸ 17 Jul 2026, 10:03 Proposed issue of securities - OCC Securities Administration
▸ 16 Jul 2026, 13:43 Notification of cessation of securities - OCC Securities Administration
▸ 14 Jul 2026, 08:47 Q4 FY26 ASX Investor Presentation Presentations
▸ 13 Jul 2026, 08:53 Quarterly Activity Report & Appendix 4C Quarterly Reports
▸ 6 Jul 2026, 08:43 Orthocell Investor Webinar Details Periodic Reports
▸ 3 Jul 2026, 08:56 Orthocell Appoints Thailand Distributor for Remplir Company Update
▸ 30 Jun 2026, 08:51 Clinical Outcomes See Expanded Use of Remplir in the Ukraine Company Update
▸ 14 May 2026, 16:15 Cleansing Notice Securities Administration
▸ 14 May 2026, 16:11 Application for quotation of securities - OCC Securities Administration
▸ 5 May 2026, 16:22 Cleansing Notice Securities Administration
▸ 5 May 2026, 16:19 Application for quotation of securities - OCC Securities Administration
▸ 4 May 2026, 09:39 Appendix 3Y - Michael McNulty Director Interests
▸ 4 May 2026, 09:36 Appendix 3Y - John Van Der Wielen Director Interests
▸ 30 Apr 2026, 09:14 First Sales of Remplir Achieved in US$75m Canadian Market Company Update
▸ 28 Apr 2026, 09:10 Compelling 90% Success Rate for Remplir in Real World Study Company Update
▸ 20 Apr 2026, 09:05 Q3 FY26 Investor Presentation Presentations
▸ 20 Apr 2026, 09:04 Quarterly Activity Report & Appendix 4C Quarterly Reports
▸ 17 Apr 2026, 09:01 First Surgical Use of Remplir in US Department of Defense Company Update
▸ 15 Apr 2026, 09:00 OCC Secures Access to 221 U.S. Military Medical Centres Company Update
▸ 15 Apr 2026, 08:25 Notification of cessation of securities - OCC Securities Administration
▸ 14 Apr 2026, 10:20 Orthocell Investor Webinar Details Presentations
▸ 8 Apr 2026, 09:06 US Section 232 Tariffs Not Expected to Affect Remplir Company Administration
▸ 31 Mar 2026, 14:43 Orthocell Investor Presentation - Broker Meets Biotech Presentations
▸ 18 Mar 2026, 09:57 Remplir Used in 23 Surgeries in Ukrainian soldiers Company Update
▸ 16 Mar 2026, 19:29 Notification of cessation of securities - OCC Securities Administration
▸ 16 Mar 2026, 18:34 Notification regarding unquoted securities - OCC Securities Administration
▸ 10 Mar 2026, 09:08 Orthocell Appoints UK Distributor for Remplir Company Update
▸ 26 Feb 2026, 08:47 Appendix 3Y - Michael McNulty Director Interests
▸ 26 Feb 2026, 08:46 Appendix 3Y - John Van Der Wielen Director Interests
▸ 24 Feb 2026, 09:02 Appendix 4D & Half-Year Financial Report Financial Results
▸ 18 Feb 2026, 12:56 Orthocell Receives $3.0m R&D Tax Refund Periodic Reports
▸ 2 Feb 2026, 09:02 US Market and Operational Update Presentations
▸ 29 Jan 2026, 10:21 Orthocell Investor Webinar Details Presentations
▸ 19 Jan 2026, 09:07 Quarterly Activity Report & Appendix 4C Quarterly Reports
▸ 16 Jan 2026, 09:01 Orthocell Finalises Strategic Investment in Marine Biomedica Company Update
▸ 6 Jan 2026, 09:33 Orthocell Posts Seventh Straight Record Revenue Quarter Company Update
▸ 22 Dec 2025, 18:10 Appendix 3Y - Paul Anderson Director Interests
▸ 22 Dec 2025, 18:06 Cleansing Notice Securities Administration
▸ 22 Dec 2025, 18:04 Application for quotation of securities - OCC Securities Administration
▸ 18 Dec 2025, 09:42 Orthocell Hits US Milestone - 100 Remplir Units Sold. Company Update
▸ 15 Dec 2025, 09:05 Remplir Regulatory Application for US$750m EU-UK Market Company Update
▸ 10 Dec 2025, 09:18 First Commercial Sales of Remplir Achieved in Hong Kong Company Update
▸ 28 Nov 2025, 18:28 Appendix 3Y - Paul Anderson Director Interests
▸ 28 Nov 2025, 18:24 Notification regarding unquoted securities - OCC Securities Administration
▸ 20 Nov 2025, 09:03 Remplir gains momentum in nerve-sparing prostate surgery Company Update
▸ 14 Nov 2025, 13:24 Cleansing Notice Securities Administration
▸ 14 Nov 2025, 13:20 Application for quotation of securities - OCC Securities Administration
▸ 6 Nov 2025, 18:25 Amended Constitution Securities Administration
▸ 6 Nov 2025, 14:50 Results of Annual General Meeting Meetings & Governance
▸ 6 Nov 2025, 09:30 AGM Addresses by Chair and Managing Director Presentations
▸ 5 Nov 2025, 08:59 2nd Distributor in Canada, Entire $75m Market Now Covered Company Update
▸ 3 Nov 2025, 09:12 Remplir Launches in Hong Kong with First Surgical Case Company Update
▸ 31 Oct 2025, 09:03 Appendix 3Y - Michael McNulty Director Interests
▸ 31 Oct 2025, 08:59 Appendix 3Y - John Van Der Wielen Director Interests
▸ 29 Oct 2025, 08:57 HK Distributor Signed as Remplir Expands in the Asian Market Company Update
▸ 24 Oct 2025, 09:50 Notification regarding unquoted securities - OCC Securities Administration
▸ 24 Oct 2025, 09:50 Cleansing Notice Securities Administration
▸ 24 Oct 2025, 09:46 Application for quotation of securities - OCC Securities Administration
▸ 21 Oct 2025, 16:32 Cleansing Notice Securities Administration
▸ 21 Oct 2025, 16:30 Application for quotation of securities - OCC Securities Administration
▸ 20 Oct 2025, 08:56 OCC Secures Rights to High-Value Bone Regeneration Tech Company Update
▸ 17 Oct 2025, 16:29 Letter, Supplementary Notice of AGM & Replacement Proxy Form Meetings & Governance
▸ 17 Oct 2025, 09:19 Proposed issue of securities - OCC Securities Administration
▸ 17 Oct 2025, 09:18 $30m Placement Sees Orthocell Positioned for Rapid Growth Capital Raising
▸ 15 Oct 2025, 09:19 Trading Halt Trading Halt / Suspension
▸ 10 Oct 2025, 09:01 Quarterly Activity Report & Appendix 4C Quarterly Reports
▸ 3 Oct 2025, 16:06 Annual Report to Shareholders Financial Results
▸ 3 Oct 2025, 16:04 Letter to Shareholders, Notice of AGM & Proxy Form Meetings & Governance
▸ 2 Oct 2025, 08:55 Another Record Revenue Quarter for Orthocell Periodic Reports
▸ 30 Sep 2025, 17:58 Cleansing Notice Securities Administration
▸ 30 Sep 2025, 17:55 Application for quotation of securities - OCC Securities Administration
▸ 30 Sep 2025, 08:57 First Distributor signed for Remplir in $75m Canadian Market Company Update
▸ 16 Sep 2025, 09:05 Remplir Use in Prostate Surgery Signals Global Opportunity Company Update
▸ 10 Sep 2025, 19:11 Date of AGM & Closing Date for Director Nominations Meetings & Governance
▸ 8 Sep 2025, 09:03 Compelling 81% Success Rate for Remplir Company Update